Testing empasiprubart vs IVIg for chronic CIDP
Treatments studied
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study tests an investigational drug called empasiprubart against standard IVIg in adults with CIDP. The goal is to see if it is safer and more effective for people who still have symptoms despite IVIg therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of typical or specific types of CIDP.
- You must have had a good response to IVIg treatment in the last 5 years.
- You must currently be on a stable dose of IVIg (at least 0.125 grams per kilogram each week).
- You must still have some disability from CIDP despite IVIg treatment.
- You cannot have other autoimmune diseases or conditions that might affect the study results.
- You cannot be using other long-acting medications that alter the immune system.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called Empasiprubart for adults with ongoing CIDP. It aims to see if fewer symptoms return and if it can replace current treatments.
This trial tests whether a new medication called riliprubart works as well as the usual IVIg treatment for people with chronic inflammatory demyelinating polyneuropathy (CIDP). It may offer another option for managing your condition.
This trial tests a new drug called DNTH103 for adults with CIDP, a condition that affects nerves and causes weakness. It aims to see if the drug can help people who are currently on treatment, have tried treatment before, or are new to treatment.
This trial tests a new medicine called empasiprubart in teenagers ages 12–17 with CIDP, a rare nerve disease that causes weakness and numbness. Researchers want to find the right dose and see if it safely reduces symptoms.
This trial tests a new drug called Imeroprubart for people with CIDP who are already on a stable treatment like steroids or immunoglobulin. The goal is to see if the drug can help control symptoms better.
This trial tests whether a blood-filtering treatment called immunoadsorption can help people with CIDP. It is for adults who are already receiving or starting IVIg or MP therapy.
Hear when a new Chronic Inflammatory Demyelinating Polyneuropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.